Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study.

Katarina MitrovaBarbora PipekMartin BortlikLudek BouchnerJan BrezinaTomas DoudaTomas DrasarPavel DrastichPremysl FaltPavel KlvanaVaclav LeksaAles NovotnyPavel SvobodaJan SkorpikJan UlbrychMarek VeinfurtBlanka ZborilovaMilan LukasDana Duricova

Published in: Therapeutic advances in gastroenterology (2021)

Vedolizumab demonstrated different placental pharmacokinetics, leading to lower drug levels in cord blood compared to maternal blood at delivery; in contrast, the placental transfer of ustekinumab seems to have a pattern similar to anti-tumour necrosis factor (TNF) agents.

Keyphrases

cord blood
ulcerative colitis
patients with inflammatory bowel disease
rheumatoid arthritis
magnetic resonance
emergency department
adverse drug
weight loss